Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing...
Year: 2024
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW...
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"),...
HOOPP delivers 9.38% return in 2023: success bolstered by strong Canadian portfolio
Jeff Wendling, President & CEO, Healthcare of Ontario Pension Plan (HOOPP) “In 2023, there was considerable economic uncertainty resulting from...
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc....
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by...
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
Tilray Introduces New Naturally Flavoured CBG Infused Cannabis Beverages
Enjoy Moments of Chill with Non-Alcoholic Mollo ‘Seltzers’TORONTO, March 13, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX:...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia’s biotherapeutic delivery system with...
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by...
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 --...
ProQR Announces Year End 2023 Operating and Financial Results
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1...
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
FendX Announces Warrant Exercises and Share for Debt Settlement
Oakville, Ontario--(Newsfile Corp. - March 13, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or...
BioNxt Reports Successful Results From ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to...
Bioz and Teledyne LABS Announce AI-Powered Partnership Enabling Easy Access to Product Citations From Scientific Publications
PALO ALTO, CA / ACCESSWIRE / March 13, 2024 / Bioz, Inc., an AI company specializing in the analysis of...